Brad-Smith

Brad Smith, Board Director

Brad Smith is the Chief Financial Officer of Homology Medicines and has an extensive track record of successfully executing financial strategies for life science companies and has raised nearly $1 billion in equity and debt financing. At Homology Medicines, he was instrumental in leading multiple private and public fundraising rounds including an $83.5 million crossover round, a $166 million initial public offering (IPO), a $144 million follow-on financing, and a $60 million equity investment from Pfizer. He also played a key role in closing a collaboration with the Novartis Institute of Biomedical Research. Prior to Homology, Mr. Smith raised nearly $200 million for Ocular Therapeutix including an IPO, a secondary offering, and a debt financing, while also negotiating a strategic alliance with Regeneron Pharmaceuticals. Prior to Ocular, he served as CFO of several other healthcare companies, including OmniGuide Surgical, SYNARC and PatientKeeper, Inc. He started his career at Coopers & Lybrand (PWC). Mr. Smith earned his B.S. in Biology from Tufts University and his MBA from the Whittemore School, University of New Hampshire.